Table 3. Cell cycle distribution of WiDr, H630 and SW1116 cells following OHP and/or TFT exposure.
|
Cell cycle distribution
|
|||
|---|---|---|---|
| Drug treatment | (%) G1 | (%) S | (%) G2M |
| WDr | |||
| Control | 46.8±3.0 | 15.2±0.9 | 38.0±2.9 |
| OHP IC75 48 h | 25.8±2.6 | 21.4±1.8 | 52.8±3.9 |
| TFT IC75 48 h | 3.4±0.6** | 59.9±3.4** | 36.7±3.1* |
| TFT IC75+OHP IC75 48 h | 18.1±4.1 | 53.4±6.0** | 28.5±3.1** |
| preTFT>OHP IC75 48 h | 30.3±1.0 | 25.4±4.3 | 44.3±5.2 |
| preTFT>TFT IC75+OHP IC75 48 h | 6.4±2.0** | 55.2±4.9** | 38.4±3.3* |
| H630 | |||
| Control | 38.9±1.2 | 24.2±0.9 | 36.9±2.0 |
| OHP IC75 48 h | 19.8±7.9 | 37.1±3.2 | 43.1±5.0 |
| TFT IC75 48 h | 12.1±5.7 | 43.9±7.1 | 44.1±5.9 |
| TFT IC75+OHP IC75 48 h | 13.6±3.5 | 49.1±2.6* | 37.3±0.9 |
| preTFT>OHP IC75 48 h | 26.0±1.4 | 30.6±1.9 | 43.4±2.9 |
| preTFT>TFT IC75+OHP IC75 48 h | 11.5±3.7 | 52.7±0.8** | 35.8±3.5 |
| SW1116 | |||
| Control | 46.9±2.6 | 23.2±2.0 | 29.9±0.7 |
| OHP IC75 48 h | 30.5±1.9 | 41.7±3.0 | 27.8±1.6 |
| TFT IC75 48 h | 8.5±1.1** | 35.8±2.5 | 55.7±2.1** |
| TFT IC75+OHP IC75 48 h | 12.7±1.2** | 49.2±2.2 | 38.1±2.6* |
| preTFT>OHP IC75 48 h | 12.6±0.8** | 36.1±2.9 | 51.3±3.7** |
| preTFT>TFT IC75+OHP IC75 48 h | 9.3±0.3** | 50.8±4.1 | 39.9±4.4* |
The cells were exposed 48 h to [IC75] of OHP, TFT or both drugs. These drug concentrations are mentioned in the legend of Table 2. preTFT: 4 h TFT pre-incubation period. Values are means±s.e.m. (n=3). Significant differences compared to OHP alone: *P<0.05; **P<0.01.